Trial Profile

A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Apr 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary)
Indications Cervical cancer; Cholangiocarcinoma; Head and neck cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms iNSITE-2
Sponsors BIND Therapeutics

06 Apr 2016 According to a BIND Therapeutics media release, based on the results of this trial, the company decided to halt further enrollment of patients with advanced cervical and head and neck cancers.
06 Apr 2016 Status changed from recruiting to discontinued, according to a Bind Therapeutics media release.
06 Apr 2016 Results published in a Bind Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com